New combo therapy aims to boost success of bile duct cancer surgery
NCT ID NCT06739252
Summary
This study tested a treatment given before surgery for bile duct cancer that has a high risk of coming back. The goal was to see if a combination of targeted liver chemotherapy, an immunotherapy drug (atezolizumab), and a blood vessel blocker (bevacizumab) could shrink tumors and improve long-term results after surgery. The trial was for patients whose cancer was still removable by surgery but had features making recurrence likely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peing University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.